144,500 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Bought by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB bought a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the 4th quarter, HoldingsChannel reports. The fund bought 144,500 shares of the biotechnology company’s stock, valued at approximately $9,593,000.

Several other hedge funds also recently made changes to their positions in the company. CWM LLC boosted its holdings in Arrowhead Pharmaceuticals by 1.4% in the fourth quarter. CWM LLC now owns 12,347 shares of the biotechnology company’s stock valued at $820,000 after acquiring an additional 168 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of Arrowhead Pharmaceuticals by 1.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 11,102 shares of the biotechnology company’s stock valued at $737,000 after buying an additional 178 shares in the last quarter. HighTower Advisors LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 0.3% during the 4th quarter. HighTower Advisors LLC now owns 133,229 shares of the biotechnology company’s stock valued at $8,845,000 after buying an additional 340 shares in the last quarter. Tsfg LLC bought a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at $25,000. Finally, Oregon Public Employees Retirement Fund boosted its holdings in shares of Arrowhead Pharmaceuticals by 1.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 31,614 shares of the biotechnology company’s stock valued at $2,099,000 after buying an additional 430 shares in the last quarter. 62.61% of the stock is owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Trading Up 0.1%

ARWR stock opened at $74.52 on Friday. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $14.30 and a 1-year high of $82.26. The company has a debt-to-equity ratio of 1.41, a current ratio of 6.23 and a quick ratio of 6.23. The company has a market capitalization of $10.50 billion, a price-to-earnings ratio of -34.66 and a beta of 1.28. The business has a 50 day simple moving average of $72.46 and a two-hundred day simple moving average of $66.71.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping the consensus estimate of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The business had revenue of $73.74 million during the quarter, compared to the consensus estimate of $73.84 million. During the same period in the prior year, the company posted $2.75 EPS. The firm’s revenue for the quarter was down 86.4% compared to the same quarter last year. Research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ARWR. Morgan Stanley raised Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $78.00 to $100.00 in a research report on Tuesday, April 21st. Sanford C. Bernstein boosted their target price on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Wall Street Zen lowered shares of Arrowhead Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Royal Bank Of Canada boosted their price objective on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $87.80.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total value of $750,000.00. Following the completion of the transaction, the insider directly owned 226,958 shares in the company, valued at $17,021,850. This represents a 4.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of the company’s stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total value of $934,328.25. Following the completion of the transaction, the chief financial officer owned 162,905 shares of the company’s stock, valued at $11,623,271.75. The trade was a 7.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 26,065 shares of company stock worth $1,912,662 in the last three months. 3.60% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.